Lyell Immunopharma (LYEL) director granted 9,250 stock options at $13.22
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Lyell Immunopharma director Richard Klausner received a grant of 9,250 stock options for common stock, each with a $13.22 exercise price and expiring on June 9, 2036. This is a compensation-related award rather than an open-market purchase.
The options will vest on the earlier of the next annual stockholder meeting following June 10, 2026 (or immediately before it if he leaves the board at that meeting) or the first anniversary of that date, assuming continuous service. Following the reporting date, he held 148,391 common shares directly and 42,166 shares indirectly through family and Delaware trusts, with beneficial ownership of the Delaware trusts disclaimed except for any pecuniary interest. All share amounts reflect a 1-for-20 reverse stock split effective May 30, 2025.
Positive
- None.
Negative
- None.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
Klausner Richard
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Option (right to buy) | 9,250 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Option (right to buy) — 9,250 shares (Direct, null);
Common Stock — 148,391 shares (Direct, null);
Common Stock — 42,166 shares (Indirect, Grantor and Trustee)
Footnotes (1)
- On May 30, 2025, the Issuer effected a 1-for-20 reverse stock split of its common stock. All share and amounts reported herein reflect the reverse stock split. Consists of 7,900 shares held by The Klausner Family Revocable Trust of May 8, 2014, 12,275 shares held by The Ariella Klausner Delaware Trust, 9,716 shares held by The Eli Klausner Delaware Trust and 12,275 shares held by The Olivia Klausner Delaware Trust (collectively, The Ariella Klausner Delaware Trust, The Eli Klausner Delaware Trust and The Olivia Klausner Delaware Trust, the "Delaware Trusts"). The Reporting Person is grantor and trustee of The Klausner Family Revocable Trust of May 8, 2014 and grantor of each of the Delaware Trusts. The JTC Trust Company (Delaware) Limited is the trustee of each of the Delaware Trusts. The Reporting Person disclaims beneficial ownership of all shares held by the Delaware Trusts except to any pecuniary interest therein The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date.
Key Figures
Option grant size: 9,250 options
Option exercise price: $13.22 per share
Option expiration: June 9, 2036
+4 more
7 metrics
Option grant size
9,250 options
Grant of options for common stock to director on June 10, 2026
Option exercise price
$13.22 per share
Exercise price for newly granted options
Option expiration
June 9, 2036
Expiration date of 9,250 stock options
Direct common shares held
148,391 shares
Direct ownership following reported transactions
Indirect common shares held
42,166 shares
Indirect holdings via family and Delaware trusts
Reverse split ratio
1-for-20
Reverse stock split effective May 30, 2025
Reverse split date
May 30, 2025
Effective date of 1-for-20 reverse stock split
Key Terms
Option (right to buy), Grant, award, or other acquisition, 1-for-20 reverse stock split, Revocable Trust, +1 more
5 terms
Option (right to buy) financial
"security_title: "Option (right to buy)""
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
1-for-20 reverse stock split financial
"the Issuer effected a 1-for-20 reverse stock split of its common stock"
Revocable Trust financial
"shares held by The Klausner Family Revocable Trust of May 8, 2014"
A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.
Delaware Trusts financial
"collectively, ... the "Delaware Trusts""
FAQ
What did Richard Klausner report in the latest LYEL insider filing?
Richard Klausner reported receiving a grant of 9,250 stock options for Lyell Immunopharma common stock. The options are a compensation-related award with a $13.22 exercise price and expire June 9, 2036, rather than an open-market share purchase or sale.
When do Richard Klausner’s new Lyell Immunopharma (LYEL) options vest?
The 9,250 options vest on the earlier of the next annual stockholder meeting after June 10, 2026, or the first anniversary of June 10, 2026. Vesting is conditioned on Klausner providing continuous service to Lyell Immunopharma through the applicable vesting date.
What is the exercise price and expiration of Klausner’s new LYEL stock options?
The newly granted 9,250 Lyell Immunopharma stock options have a $13.22 per-share exercise price and expire on June 9, 2036. These options relate to common stock and are structured as a right to buy shares at that fixed exercise price before expiration.
How did Lyell Immunopharma’s reverse stock split affect Klausner’s reported holdings?
Lyell Immunopharma completed a 1-for-20 reverse stock split of its common stock effective May 30, 2025. All share and option amounts in Klausner’s filing, including direct and indirect holdings and the 9,250-option grant, are presented on a post–reverse-split basis.